This application is proposed to address the molecular oncogenic properties of mutant p53. p53 tumor suppressor is a sequence-specific DNA-binding transcription factor. Wild-type p53 is activated in response to various stress signals, such as DNA damage, oncogene activation, and hypoxia. Following its activation, p53 suppresses damaged cells to proliferate by inducing downstream effects, such as cell cycle arrest and apoptosis. However, mutations in the p53 gene abrogate its transcriptional activity, leading to the uncontrolled proliferation characteristic of tumor cells. As a result, mutations of the p53 gene are selected for in greater than 50% of all human cancers. A vast majority of p53 mutations occur in its DNA-binding domain, rendering p53 defective in its DNA binding and transcriptional activities. This represents the classical loss of function mutation for a tumor suppressor. Interestingly, in addition to loss of function, many p53 mutants obtain additional activities, called gain of function. It is well known that in a cell carrying both wild-type and mutant p53, the mutant p53 acquires its gain of function by forming a heterotetramer with, and inhibiting the activity of, wild-type p53. However, the vast majority of tumor cells, which over-express a mutant p53, do not carry a wild-type p53. Thus, mutant p53 gain of function in these tumor cells must be due to its tumor-promoting activity independent of the inhibition of wild-type p53. To further analyze how mutant p53 obtains its gain of function, the following specific aims are proposed: (1) to determine whether mutant p53 is required for maintaining the transformed phenotypes of tumor cells in evading apoptosis and enhanced potentials in proliferation and invasion;(2) to determine whether various classes of p53 mutants differ in their ability to maintain the transformed phenotypes of tumor cells;and (3) to determine whether mutant p53 still functions as a transcription factor that regulates genes involved in promoting survival or inhibiting anti-growth signals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA121137-05
Application #
7762854
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Watson, Joanna M
Project Start
2007-02-01
Project End
2011-12-31
Budget Start
2010-01-01
Budget End
2010-12-31
Support Year
5
Fiscal Year
2010
Total Cost
$288,800
Indirect Cost
Name
University of California Davis
Department
Surgery
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Ren, Cong; Zhang, Jin; Yan, Wensheng et al. (2016) RNA-binding Protein PCBP2 Regulates p73 Expression and p73-dependent Antioxidant Defense. J Biol Chem 291:9629-37
Lucchesi, Chris; Zhang, Jin; Chen, Xinbin (2016) Modulation of the p53 family network by RNA-binding proteins. Transl Cancer Res 5:676-684
Yan, Wensheng; Scoumanne, Ariane; Jung, Yong-Sam et al. (2016) Mice deficient in poly(C)-binding protein 4 are susceptible to spontaneous tumors through increased expression of ZFP871 that targets p53 for degradation. Genes Dev 30:522-34
Zhang, Min; Zhang, Jin; Yan, Wensheng et al. (2016) p73 expression is regulated by ribosomal protein RPL26 through mRNA translation and protein stability. Oncotarget 7:78255-78268
Zhang, M; Xu, E; Zhang, J et al. (2015) PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38. Oncogene 34:5900-11
Cho, Seong-Jun; Teng, I-Fang; Zhang, Min et al. (2015) Hypoxia-inducible factor 1 alpha is regulated by RBM38, a RNA-binding protein and a p53 family target, via mRNA translation. Oncotarget 6:305-16
Zhang, Yanhong; Young, Ashley; Zhang, Jin et al. (2015) P73 tumor suppressor and its targets, p21 and PUMA, are required for madin-darby canine kidney cell morphogenesis by maintaining an appropriate level of epithelial to mesenchymal transition. Oncotarget 6:13994-4004
Cao, Ruibing; Zhang, Jin; Zhang, Min et al. (2015) PPM1D regulates p21 expression via dephoshporylation at serine 123. Cell Cycle 14:641-7
Jiang, Yuqian; Zhang, Min; Qian, Yingjuan et al. (2014) Rbm24, an RNA-binding protein and a target of p53, regulates p21 expression via mRNA stability. J Biol Chem 289:3164-75
Zhang, Jin; Xu, Enshun; Ren, Cong et al. (2014) Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors. Proc Natl Acad Sci U S A 111:18637-42

Showing the most recent 10 out of 33 publications